In this randomized , multicenter , double-blind , placebo-controlled , phase III trial , adults with RA were randomly assigned to receive IV placebo ( n = @ ) or golimumab @ mg/kg ( n = @ ) infusions at Week @ , Week @ , and every @ weeks thereafter .